Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 1
4(57.1%)
Phase 2
3(42.9%)
7Total
Phase 1(4)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07461220Phase 1Recruiting

Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy

Role: lead

NCT06699628Phase 1Completed

Phase I Trial Evaluating the Pharmacokinetics of Single Ascending Oral Doses of IRL757 in Healthy Elderly Volunteers

Role: lead

NCT06493045Phase 1Completed

First-In-Human (FIH) Trial Evaluating the Safety and Tolerability of Single and Multiple Ascending Oral Doses of IRL757 in Healthy Volunteers

Role: lead

NCT05258071Phase 2Completed

A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients with Parkinson's Disease (PD)

Role: lead

NCT04435431Phase 2Completed

A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia

Role: lead

NCT03368170Phase 2Completed

Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia

Role: lead

NCT03531060Phase 1Completed

A Clinical Study of IRL790 in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia

Role: lead

All 7 trials loaded